Metraipolis › archive › dc_65e5471f2152

Identification of predictive biomarkers and dose optimization for camrelizumab combined with apatinib in the treatment of advanced hepatocellular carcinoma: a… — Europe PMC PMID:41782865

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41782865
DOI
10.3389/fimmu.2026.1617227
License (as archived)
solo-consultazione
Archived
2026-11-05T17:19:15.968Z
SHA-256 of the archived text
3df09a0ff75070c8db0ffae57c5cc47817871dcd5e2e091423fb1e4d9b791d85
Stable URL of this page
https://metraipolis.com/documento/dc_65e5471f2152

How to cite

Identification of predictive biomarkers and dose optimization for camrelizumab combined with apatinib in the treatment of advanced hepatocellular carcinoma: a… — Europe PMC PMID:41782865 — Europe PMC (en), https://europepmc.org/article/MED/41782865 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_65e5471f2152 (Metraipolis archive dc_65e5471f2152, sha256 3df09a0ff75070c8db0ffae57c5cc47817871dcd5e2e091423fb1e4d9b791d85)
BibTeX
@misc{dc65e5471f2152,
  title = {Identification of predictive biomarkers and dose optimization for camrelizumab combined with apatinib in the treatment of advanced hepatocellular carcinoma: a… — Europe PMC PMID:41782865},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41782865},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_65e5471f2152; sha256 3df09a0ff75070c8db0ffae57c5cc47817871dcd5e2e091423fb1e4d9b791d85},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41782865. Agents can read the archived copy with the MCP tool read_document.